GPR119

GPR119

A gene on chromosome Xq26.1 that encodes an orphan G protein-coupled receptor.
References in periodicals archive ?
Dr mml explains that during the early days of the Human Genome Project, the GPR119 gene, coding for a 7TM receptor, was identified and shown to have a unique pattern of expression in pancreatic islets and in some regions of the gastrointestinal tract in humans.
Our data have shown, for the first time, that GPR119 is selectively expressed in alpha cells, not beta cells, and is most likely involved in regulating glucagon secretion not insulin secretion directly.
will be presenting a 30-minute scientific presentation entitled "Creating and Using a Physiological Model to Support Development of a GPR119 Agonist Diabetes Therapy.
2) Reduction of Food Consumption via Peripheral Mechanisms 2a) Cannabinoid 1 (CB1) receptor antagonist 2b) GPR119 agonists 2c) Opioid Receptors 2d) PPAR Agonists 2e) Antagonists of Glucocorticoid Receptor (GCCR) 2f) Others
In addition, OSI focuses its development resources on advancing high quality and differentiated development assets, including OSI's IGF-1R/IR inhibitor, OSI-906, and its GPR119 agonist, PSN821, both of which have the potential to be blockbusters, "first-in-class" and/or "best-in-class" and are highly competitive in these much sought after target areas.
PSN821, an oral GPR119 agonist being developed for the treatment of type 2 diabetes and PSN602, an oral dual monoamine reuptake inhibitor and 5-HT1A agonist being developed for the treatment of obesity, were discovered by OSI's diabetes and obesity R&D team and are wholly owned by OSI.
Nasdaq: OSIP) announced today that it has initiated a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the Company is developing for the treatment of type 2 diabetes.
PSN821 is a novel, orally available agonist of the G-protein coupled receptor GPR119 which stimulates the release of both insulin and glucagon-like peptide-1 (GLP-1).
Two classes of emerging metabolic approaches stand out from the remainder: the glucose-dependent stimulation of insulin release or secretion by glucokinase activators or direct activation of the GPR119 receptor and the suppression of glucocorticoid action by inhibition of the 11-beta hydroxysteroid dehyrogenase type 1 (HSD-1) or directly of the glucocorticoid receptor.
Preclinical data on PSN821, a novel, orally available agonist of the G-protein coupled receptor GPR119, being developed for the treatment of type 2 diabetes and obesity, were presented in an oral presentation.
PSN821: A Novel Oral GPR119 Agonist for the Treatment of Type 2 Diabetes Producing Substantial Glucose Lowering and Weight Loss in Rats (Matthew Fyfe et al.
Also presented were preclinical data on novel, orally available agonists of the G-protein coupled receptor GPR119 for the potential treatment of obesity, diabetes and associated metabolic disorders.